PT-141

Overview

Evidence tier: 5 — editorial framing of the peptide-page entity context.

PT-141 — generic name bremelanotide, brand name Vyleesi — is the only FDA-approved peptide for sexual dysfunction. It was approved in June 2019 specifically for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, after pivotal trials (RECONNECT) enrolling 1,247 women demonstrated statistically significant improvement in sexual desire and reduction of distress.

The molecule's distinguishing feature is its mechanism. Conventional sexual-dysfunction drugs — sildenafil, tadalafil, vardenafil — act peripherally on smooth muscle and blood vessels. They enable arousal in the presence of desire but do nothing for desire itself. PT-141 acts centrally, in the brain, on the melanocortin receptor system. It addresses the desire and arousal pathways themselves rather than the vascular response.

That central mechanism produces a different effect profile and a different side-effect profile from PDE5 inhibitors. The trade-off pattern matters when patients consider it.

How it works

Evidence tier: 2 — mechanism documented in published pharmacology literature.

PT-141 is a non-selective melanocortin receptor agonist with primary activity at MC3R and MC4R receptors in the central nervous system. Activation of these receptors in specific hypothalamic and limbic regions modulates dopaminergic and oxytocin pathways involved in sexual desire and arousal — the same pathways that natural arousal recruits.

The downstream effect is an enhancement of subjective sexual desire and physiological arousal that is fundamentally upstream of the vascular response to arousal. This is why PT-141 can be effective in men and women with erectile dysfunction or arousal disorders that are partly or wholly central in origin, where PDE5 inhibitors fail.

The trade-off: melanocortin receptors are not exclusive to sexual pathways. MC1R activity contributes to skin pigmentation; chronic high-dose use produces hyperpigmentation in some patients. Melanocortin receptors in the brainstem and cardiovascular regions contribute to the side-effect profile — particularly the transient blood pressure elevation seen in many patients.

Evidence, on-label vs off-label, and side effects

Evidence tier: 2 — references summarized in the body; see Trial readouts section below for primary-source detail.

On-label evidence is strong:

• RECONNECT trials (2016–2017): n=1,247 premenopausal women with HSDD, randomized 1:1 to bremelanotide vs placebo. Statistically significant improvement in Female Sexual Function Index desire score and reduction in associated distress. Tier 1.
• Long-term open-label extension showed sustained effect with continued use.

Off-label use is common — for men with erectile dysfunction unresponsive to PDE5 inhibitors, for postmenopausal women, for couples seeking a desire enhancer rather than just an arousal enabler. Off-label efficacy data is limited; published trials in these populations are sparse.

Side effects:

• Nausea is the most common — affects up to 40% of patients on first dose, decreases substantially with subsequent use.
• Flushing.
• Injection-site reactions.
• Headache.
• Transient blood pressure elevation — a real cardiovascular consideration. Contraindicated in uncontrolled hypertension or established cardiovascular disease.
• Hyperpigmentation with chronic high-dose use.
• Theoretical interaction with monoaminergic drugs and stimulants.

Avoid in pregnancy, lactation, recent or untreated cardiovascular disease, severe hypertension. Patients with history of melanoma or atypical nevi should be evaluated before use given MC1R activity.

Practical considerations

Evidence tier: 5 — community-evolved dose-range guidance; not RCT-derived.

• On-label dosing. Vyleesi: 1.75 mg subcutaneously, as needed, 45 minutes before anticipated sexual activity. Maximum 8 doses per month.
• Off-label dosing. Research-chemical PT-141 is dosed by community protocols at 0.5–2 mg subcutaneously or 5–20 mg intranasally. Intranasal bioavailability is significantly lower (~20%) than subcutaneous (~100%), requiring proportionally higher doses.
• Onset and duration. Effect begins 30–60 minutes post-dose; subjective effect typically lasts 4–8 hours.
• Cost. Branded Vyleesi is expensive — typically $50–100 per autoinjector, often not insurance-covered. Compounded or research-chemical versions cost less but carry the usual quality-verification burden.
• First-dose strategy. Given the high nausea rate on first dose, many clinicians recommend starting with a low test dose (e.g. 0.5 mg) at home, not before a sexual encounter, to characterize the individual side-effect response.

Where to go from here

Evidence tier: 5 — editorial framing of the peptide-page entity context.

For the broader Sexual Health pillar including melanotan II and other less-evidenced peptides, see the goal-based hub. For the pharmacology of melanocortin receptors and other MSH-derived peptides like KPV, see the cognitive and immune-gut pillars.

Related on Peptide Story

• Sexual Health pillar — central-mechanism libido peptides
• Melanotan-II vs PT-141 — safety comparison
• PT-141 nausea management protocols

References

• Kingsberg S.A. et al. 2019. RECONNECT: Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol.
• Pfaus J. et al. 2007. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med.